Article
A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies.
Pediatric pulmonology - 1 Sept 2011
Taylor Chelsea, Commander Clayton W, Collaco Joseph M, Strug Lisa J, Li Weili, Wright Fred A, Webel Aaron D, Pace Rhonda G, Stonebraker Jaclyn R, Naughton Kathleen, Dorfman Ruslan, Sandford Andrew, Blackman Scott M, Berthiaume Yves, Paré Peter, Drumm Mitchell L, Zielenski Julian, Durie Peter, Cutting Garry R, Knowles Michael R, Corey Mary
Abstract excerpt
Genetic studies of lung disease in cystic fibrosis (CF) are hampered by the lack of a severity measure that accounts for chronic disease progression and mortality attrition. Further, combining analyses across studies requires common phenotypes that are robust to study design and patient ascertainment. Using data from the North American Cystic Fibrosis Modifier Consortium (Canadian Consortium for CF Genetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.